...

首页> 外文期刊>European Journal of Cancer Supplements >93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

【24h】

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

机译：93 POSTER I期每日口服AZD2171（血管内皮生长因子受体（VEGFR）的抑制剂）与奥沙利铂和5-Fu输注（mFOLFOX6）联合治疗晚期结直肠癌（CRC）的研究：美国国家癌症研究加拿大癌症研究所临床试验小组

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
E.Chen; D.Jonker; M.Maclean; J.Wells; S.Mathews; J.Robertson; L.Seymour;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. 719 POSTER Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients (pts) with advanced colorectal cancer (CRC) [J] . E.Chen, D.Jonker, I.Gauthier, European Journal of Cancer Supplements . 2007,第4期

机译：719 POSTER AZD2171与奥沙利铂和5-FU输注（mFOLFOX6）联合用于晚期大肠癌（CRC）患者的I期研究
2. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Ins [J] . Laurie SA, Gauthier I, Arnold A, Journal of Clinical Oncology . 2008,第11期

机译：晚期非小细胞肺癌患者每日口服AZD2171（血管内皮生长因子酪氨酸激酶抑制剂，与卡铂和紫杉醇联合使用）的第一阶段和药代动力学研究：美国国家癌症研究所
3. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Natio [J] . Goss G, Shepherd FA, Laurie S, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2009,第5期

机译：晚期非小细胞肺癌患者每日口服西地尼布（血管内皮生长因子酪氨酸激酶抑制剂）联合顺铂和吉西他滨的I期和药代动力学研究：Natio研究
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Womens Cancers: A Dose-Escalation Phase I Study [O] . Jung-Min Lee, Ashley Cimino-Mathews, Cody J. Peer, -1

机译：程序性死亡配体1抑制剂Durvalumab与聚（ADP-核糖）聚合酶抑制剂Olaparib或血管内皮生长因子受体1-3抑制剂Cediranib在女性癌症中的安全性和临床活性：剂量递增I期研究
6. PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). [O] . Laurie Scott A., Crabb Simon, Arnold Andrew, 2007

机译：PD3-2-7：在晚期非小细胞肺癌（NSCLC）的血管内皮生长因子受体（VEGFR）抑制剂联合铂类化疗的试验中，肿瘤空化对反应评估的意义：加拿大国家癌症研究所临床试验小组（NCIC CTG）。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号